Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02008292 · ClinicalTrials.gov registry record · NA
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT02008292 is a NA study that has completed, run by Yale University. The registered enrollment target is 80 participants.
The verdict
NCT02008292, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in schizophrenic smoking and nonsmoking subjects. We hypothesize that physostigmine-induced elevated ACh levels will lead to a reduction in the availability of nicotinic receptors for the binding of the radioligand. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects. We hypothesize there will be greater increase in ACh level (or greater reduction in radio tracer binding) in smoking as compared to nonsmoking subjects with schizophrenia, but the extent of this change will be different than in controls. We are also measuring the sensitivity of PHNO binding to changes in dopamine levels in healthy smoking and nonsmoking subjects before and after amphetamine challenge.
Interventions
- DRUG Physostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2013-09 |
| Est. Completion | 2021-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02008292
The ClinicalTrials.gov registry entry for NCT02008292 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Physostigmine is the first listed.
NCT02008292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02008292 about?
NCT02008292 is a clinical study titled "Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors". The purpose of the study is to measure the sensitivity of NCFHEB binding to changes in endogenous acetylcholine levels in healthy smoking and nonsmoking subjects, and in schizophrenic smoking and nonsmoking subjects. We hypothesize that physostigmine-induced elevated ACh levels will lead to a reduct...
What is the current status of trial NCT02008292?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2013-09. Estimated completion is 2021-12.
What interventions are being tested in trial NCT02008292?
The interventions under investigation include: Physostigmine (DRUG).
Who is sponsoring clinical trial NCT02008292?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.